MedTrace Logo

The Effect of ASTARTE™ on Recurrent Urinary Tract Infection

NCT05553652 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2022-09-23

No results posted yet for this study

Summary

Investigate the effect of dietary supplements/probiotic ASTARTE™ ( L. crispatus, L. rhamnosus, L. jensenii, L. gasseri) on the microbiome composition in the intestine and vagina and thereby a reduction of risk factors for the development of rUTI during 6 months of intervention in women aged 18-40 years. This is measured by the incidence of symptomatic UTI.

Conditions

  • Recurrent Urinary Tract Infection

Interventions

DIETARY_SUPPLEMENT

ASTARTE™ oral capsules

1 Capsule daily for 6 months

DIETARY_SUPPLEMENT

Placebo oral capsules

1 Capsule daily for 6 months

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Andreas Petersen, DM. PhD · Hvidovre Hospital, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2024-08-01
Completion
2027-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05553652 on ClinicalTrials.gov